v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues    
Royalty $ 0 $ 1,369
Service 228,138 175,476
Product 1,005,373 598,457
Total Revenues 1,233,511 775,302
Operating Expenses    
Research and development 14,406,486 19,551,523
General and administrative 8,487,562 10,368,314
Sales and marketing 5,364,433 6,843,160
Total Operating Expenses 28,258,481 36,762,997
Operating Loss (27,024,970) (35,987,695)
Other Income (Expenses)    
Grant income 103,368 214,451
Loss on disposal of fixed assets (34,731) (15,843)
Interest income 9,947 93,324
Interest expense (340,362) (221,622)
Gain on change in fair value of warrant liability 28,763 240,311
Total Other Income (Expenses) (233,015) 310,621
Net Loss (27,257,985) (35,677,074)
Net Loss attributable to Non-Controlling Interest 290,149 357,996
Net Loss attributable to VolitionRx Limited Stockholders (26,967,836) (35,319,078)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 141,691 16,843
Net Comprehensive Loss $ (27,116,294) $ (35,660,231)
Loss Per Common Share Attributable to Common Stockholders - Basic and Diluted $ (0.31) $ (0.50)
Weighted Average Shares Outstanding - Basic and Diluted 86,531,172 71,234,565

Source